Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Provention Bio, Inc. - Common Stock
(NQ:
PRVB
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Provention Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Provention Bio Resubmits Teplizumab Application In US For Type-1 Diabetes
↗
February 22, 2022
Provention Bio Inc (NASDAQ: PRVB) has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 03, 2022
Gainers Cidara Therapeutics (NASDAQ:CDTX)...
Via
Benzinga
64 Biggest Movers From Yesterday
↗
February 01, 2022
Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a...
Via
Benzinga
FDA Gives Green Signal To Provention Bio's Delaying Diabetes Med Resubmission
↗
January 28, 2022
Provention Bio Inc (NASDAQ: PRVB) said that it had resolved the comparability concerns with the FDA, and
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
↗
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
January 31, 2022
Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock...
Via
Benzinga
Looking Into Provention Bio Inc's Recent Short Interest
↗
January 31, 2022
Provention Bio Inc's (NASDAQ:PRVB) short percent of float has risen 4.37% since last its last report. The company recently reported that it has 3.31 million shares sold short,...
Via
Benzinga
52 Biggest Movers From Friday
↗
January 31, 2022
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
Mid-Afternoon Market Update: Gold Records Lowest Finish In Over Six Weeks; Clearfield Shares Gain On Upbeat Results
↗
January 28, 2022
US stocks gained toward the end of trading session after opening on a weak note. Apple Inc. (NASDAQ: AAPL) reported better-than-expected earnings results for its first quarter...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
January 28, 2022
Gainers Provention Bio (NASDAQ:PRVB) stoc...
Via
Benzinga
Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2%
↗
January 28, 2022
US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (...
Via
Benzinga
33 Stocks Moving In Friday's Mid-Day Session
↗
January 28, 2022
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
↗
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 28, 2022
Gainers Provention Bio (NASDAQ:PRVB) shares increased by 16.8% to $3.97 during Friday's pre-market session. The market value of their outstanding shares is at $251.5...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
January 28, 2022
Good morning, investor! The week is almost done but we're not slacking as we check out the biggest pre-market stock movers for Friday!
Via
InvestorPlace
21 Stocks Moving in Friday's Pre-Market Session
↗
January 28, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these penny stocks insiders are buying Losers...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
January 27, 2022
Gainers Avidity Biosciences (NASDAQ:RNA) s...
Via
Benzinga
Provention Bio Starts Mid-Stage Lupus Trial; Data Expected In 2024
↗
January 21, 2022
Provention Bio Inc (NASDAQ: PRVB) has initiated the Phase 2a PREVAIL-2 study evaluating PRV-3279 in systemic lupus erythematosus (SLE). PRV-3279 is a humanized...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
January 19, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...
Via
Benzinga
61 Biggest Movers From Yesterday
↗
November 23, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...
Via
Benzinga
Provention Bio Shares Gain On Teplizumab Regulatory Update For Type 1 Diabetes
↗
November 22, 2021
The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic...
Via
Benzinga
40 Stocks Moving In Monday's Mid-Day Session
↗
November 22, 2021
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...
Via
Benzinga
Provention Bio, inc (PRVB) Q3 2021 Earnings Call Transcript
↗
November 06, 2021
PRVB earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
↗
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
↗
October 26, 2021
Provention Bio Inc (NASDAQ: PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B (...
Via
Benzinga
Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
↗
October 01, 2021
Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for...
Via
Benzinga
Provention Bio, inc (PRVB) Q2 2021 Earnings Call Transcript
↗
August 06, 2021
PRVB earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today